Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 38% Improvement Relative Risk HCQ  de Gonzalo-Calvo et al.  ICU PATIENTS Is very late treatment with HCQ beneficial for COVID-19? Retrospective 491 patients in Spain (March 2020 - February 2021) Lower mortality with HCQ (not stat. sig., p=0.23) c19hcq.org de Gonzalo-Calvo et al., Respiratory R.., Jun 2023 Favors HCQ Favors control

A blood microRNA classifier for the prediction of ICU mortality in COVID-19 patients: a multicenter validation study

de Gonzalo-Calvo et al., Respiratory Research, doi:10.1186/s12931-023-02462-x, NCT04457505
Jun 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Retrospective 491 ICU patients in Spain showing lower mortality with HCQ without statistical significance in unadjusted results.
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 37.6% lower, RR 0.62, p = 0.23, treatment 6 of 32 (18.8%), control 138 of 459 (30.1%), NNT 8.8.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
de Gonzalo-Calvo et al., 17 Jun 2023, retrospective, Spain, peer-reviewed, median age 65.0, 46 authors, study period March 2020 - February 2021, trial NCT04457505 (history). Contact: febarbe.lleida.ics@gencat.cat.
This PaperHCQAll
A blood microRNA classifier for the prediction of ICU mortality in COVID-19 patients: a multicenter validation study
David De Gonzalo-Calvo, Marta Molinero, Iván D Benítez, Manel Perez-Pons, Nadia García-Mateo, Alicia Ortega, Tamara Postigo, María C García-Hidalgo, Thalia Belmonte, Carlos Rodríguez-Muñoz, Jessica González, Gerard Torres, Clara Gort-Paniello, Anna Moncusí-Moix, Ángel Estella, Luis Tamayo Lomas, Amalia Martínez De La Gándara, Lorenzo Socias, Yhivian Peñasco, Maria Del Carmen De La Torre, Elena Bustamante-Munguira, Elena Gallego Curto, Ignacio Martínez Varela, María Cruz Martin Delgado, Pablo Vidal-Cortés, Juan López Messa, Felipe Pérez-García, Jesús Caballero, José M Añón, Ana Loza-Vázquez, Nieves Carbonell, Judith Marin-Corral, Ruth Noemí Jorge García, Carmen Barberà, Adrián Ceccato, Laia Fernández-Barat, Ricard Ferrer, Dario Garcia-Gasulla, Jose Ángel Lorente-Balanza, Rosario Menéndez, Ana Motos, Oscar Peñuelas, Jordi Riera, Jesús F Bermejo-Martin, Antoni Torres, Ferran Barbé
Respiratory Research, doi:10.1186/s12931-023-02462-x
Background The identification of critically ill COVID-19 patients at risk of fatal outcomes remains a challenge. Here, we first validated candidate microRNAs (miRNAs) as biomarkers for clinical decision-making in critically ill patients. Second, we constructed a blood miRNA classifier for the early prediction of adverse outcomes in the ICU. Methods This was a multicenter, observational and retrospective/prospective study including 503 critically ill patients admitted to the ICU from 19 hospitals. qPCR assays were performed in plasma samples collected within the first 48 h upon admission. A 16-miRNA panel was designed based on recently published data from our group. Results Nine miRNAs were validated as biomarkers of all-cause in-ICU mortality in the independent cohort of critically ill patients (FDR < 0.05). Cox regression analysis revealed that low expression levels of eight miRNAs were associated with a higher risk of death (HR from 1.56 to 2.61). LASSO regression for variable selection was used to construct a miRNA classifier. A 4-blood miRNA signature composed of miR-16-5p, miR-192-5p, miR-323a-3p and miR-451a predicts the risk of all-cause in-ICU mortality (HR 2.5). Kaplan-Meier analysis confirmed these findings. The miRNA signature provides a significant increase in the prognostic capacity of conventional scores, APACHE-II (C-index 0.71, DeLong test p-value 0.055) and SOFA (C-index 0.67, DeLong test p-value 0.001), and a risk model based on clinical predictors (C-index 0.74, DeLong test-p-value 0.035). For 28-day and 90-day mortality, the classifier also
Abbreviations Declarations Ethics approval and consent to participate The study protocol was approved by the respective ethics committee of each participating hospital. The study was designed and conducted in compliance with the Declaration of Helsinki and national and international law on data protection. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Battaglini, Lopes-Pacheco, Castro-Faria-Neto, Pelosi, Rocco, Laboratory biomarkers for diagnosis and prognosis in COVID-19, Front Immunol
Blanco-Domínguez, Sánchez-Díaz, De La Fuente, Borreguero, Matesanz-Marín et al., A Novel circulating MicroRNA for the detection of Acute Myocarditis, N Engl J Med
Carbonell, Urgelés, Rodríguez, Bodí, Martín-Loeches et al., Mortality comparison between the first and second/third waves among 3,795 critical COVID-19 patients with pneumonia admitted to the ICU: a multicentre retrospective cohort study, Lancet Reg Health-Eur
De Bruin, Bos, Van Roon, Boer, Schuurman et al., Clinical features and prognostic factors in Covid-19: a prospective cohort study, EBioMedicine
De Gonzalo-Calvo, Benítez, Pinilla, Carratalá, Moncusí-Moix et al., Circulating microRNA profiles predict the severity of COVID-19 in hospitalized patients, Transl Res
Devaux, Pinet, De Gonzalo-Calvo, The non-coding transcriptome as a New Player in Intercellular Communication, Front Mol Biosci
Dongelmans, Termorshuizen, Brinkman, Bakhshi-Raiez, Arbous et al., Characteristics and outcome of COVID-19 patients admitted to the ICU: a nationwide cohort study on the comparison between the first and the consecutive upsurges of the second wave of the COVID-19 pandemic in the Netherlands, Ann Intensive Care
Evangelou, Veroutis, Paschalaki, Foukas, Lagopati et al., Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis, Eur Respir J
Fernández-Pato, Virseda-Berdices, Resino, Ryan, Martínez-González et al., Plasma miRNA profile at COVID-19 onset predicts severity status and mortality, Emerg Microbes Infect
Giuliani, Matacchione, Ramini, Di Rosa, Bonfigli et al., Circulating miR-320b and mir-483-5p levels are associated with COVID-19 in-hospital mortality, Mech Ageing Dev
Gorog, Storey, Gurbel, Tantry, Berger et al., Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 thrombosis biomarkers Colloquium, Nat Rev Cardiol
Gustafson, Ngai, Wu, Hou, Schoffel et al., Cardiovascular signatures of COVID-19 predict mortality and identify barrier stabilizing therapies, EBioMedicine
Hermine, Porcher, Resche-Rigon, Tharaux, Ravaud, Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORI-MUNO-19 collaborative group, Eur Respir J
Hothorn, Lausen, On the exact distribution of maximally selected rank statistics, Comput Stat Data Anal
Kim, Park, Kang, Lee, Kim et al., Expression analyses of MicroRNAs in Hamster lung tissues infected by SARS-CoV-2, Mol Cells
Magen, Yacovzada, Yanowski, Coenen-Stass, Grosskreutz et al., Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis, Nat Neurosci
Matarese, Gambardella, Sardu, Santulli, miR-98 regulates TMPRSS2 expression in human endothelial cells: key implications for COVID-19, Biomedicines
Mcdonald, Enguita, Taylor, Griffin, Priebe et al., Role of miR-2392 in driving SARS-CoV-2 infection, Cell Rep
Molinero, Benítez, González, Gort-Paniello, Moncusí-Moix et al., Bronchial aspirate-based profiling identifies MicroRNA Signatures Associated with COVID-19 and Fatal Disease in critically ill patients, Front Med (Lausanne)
Pinilla, Barbé, De, Calvo, MicroRNAs to guide medical decisionmaking in obstructive sleep apnea: a review, Sleep Med Rev
Poore, Ko, Valente, Henao, Sumner et al., A miRNA host response signature accurately discriminates Acute respiratory infection etiologies, Front Microbiol
Raut, Schöttker, Holleczek, Guo, Bhardwaj et al., A microRNA panel compared to environmental and polygenic scores for colorectal cancer risk prediction, Nat Commun
Recchiuti, Patruno, Mattoscio, Isopi, Pomilio et al., Resolvin D1 and D2 reduce SARS-CoV-2-induced inflammatory responses in cystic fibrosis macrophages, FASEB J
Ritchie, Phipson, Wu, Hu, Law et al., Limma powers differential expression analyses for RNA-sequencing and microarray studies, Nucleic Acids Res
Torres, Motos, Ceccato, Bermejo-Martin, De Gonzalo-Calvo et al., Methodology of a large Multicenter Observational Study of patients with COVID-19 in spanish intensive care units, Arch Bronconeumol
Torres, Motos, Riera, Fernández-Barat, Ceccato et al., The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients, Crit Care
Täubel, Hauke, Rump, Viereck, Batkai et al., Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human phase 1b randomized, double-blind, placebo-controlled study, Eur Heart J
Wilson, Kealy, James, Plowman, Newling et al., Integrated miRNA/cytokine/chemokine profiling reveals severity-associated step changes and principal correlates of fatality in COVID-19. iScience
Wynants, Van Calster, Collins, Riley, Heinze et al., Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal, BMJ
Yang, Zhao, Li, Liu, Zhu et al., Downregulated miR-451a as a feature of the plasma cfRNA landscape reveals regulatory networks of IL-6/ IL-6R-associated cytokine storms in COVID-19 patients, Cell Mol Immunol
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit